Neurogene

Neurogene licenses or acquires gene-therapy programs that have demonstrated preclinical scientific validation but require clinical, regulatory, and manufacturing execution to reach patients. The firm focuses exclusively on rare, monogenic neurological diseases — conditions caused by a single gene mutation where delivering a functional copy of the gene to the nervous system can theoretically halt or reverse disease progression. The lead program targets Rett syndrome, a severe neurodevelopmental disorder with an established genetic driver and no approved disease-modifying therapy.

Programs are selected based on clarity of genetic target, availability of suitable animal models, feasibility of AAV-mediated delivery to the relevant central nervous system cell type, and the presence of a measurable clinical endpoint. Neurogene seeks assets from academic institutions or early-stage biotech companies where the initial scientific work is complete but the operational path — vector manufacturing, IND filing, clinical-trial design — has not been built. Rachel McMinn's prior career as a sell-side biotech analyst shapes the portfolio-construction logic around defined clinical-readout timelines rather than platform optionality.

NGN-401 is an investigational AAV-based gene therapy for Rett syndrome, delivered via a single intrathecal injection. It carries the MECP2 gene with an autoregulatory feedback mechanism — an expression-control system designed to prevent the toxicity associated with MECP2 overexpression, which has been a limitation in prior Rett gene-therapy attempts. The program entered a Phase 1/2 clinical trial in 2023, with initial data expected to inform the regulatory pathway and the design of a potential registrational study.

Rachel McMinn, the founder and CEO, leads all major strategic and capital-allocation decisions. Her background includes approximately a decade as a senior biotechnology equity research analyst at Bank of America Merrill Lynch, where she covered gene therapy and rare disease companies. The executive team is lean, consistent with a clinical-stage biotechnology company operating a focused pipeline, and McMinn's dual background in finance and science creates a centralized decision-making dynamic atypical of larger discovery-platform biotechs.

Neurogene became a publicly listed company in December 2021 through a business combination with a SPAC, Neoleukin Therapeutics (later renamed Neurogene Inc.), in a transaction that provided approximately $150 million in gross proceeds. As a public company, future financing is expected to come from equity offerings, potential strategic partnerships, or non-dilutive grant funding. The firm does not maintain a venture-capital-style fund structure or manage third-party capital.

Neurogene operates its own process-development and manufacturing-scale-up capabilities at a facility in Cambridge, Massachusetts. This internal CMC function is central to the firm's thesis that manufacturing and quality control represent the primary translational bottleneck for academic gene-therapy programs. Controlling vector production and analytical methods internally reduces the dependency on contract manufacturing organizations and allows tighter integration between process development and regulatory-filing strategy.

The governance is anchored by a founder-CEO with no external capital-pool mandate who reports to a public-company board. Because Neurogene does not operate a discovery platform, internal resources are not divided between early-stage research and clinical execution, removing the resource competition that typically exists in platform biotech companies. The reverse-merger listing created a single public entity with a defined cash runway tied to specific clinical milestones, which acts as a governance forcing function for capital discipline.